Portage Biotech Inc. (PRTG)
- Previous Close
11.85 - Open
11.55 - Bid 11.78 x 100
- Ask --
- Day's Range
10.80 - 12.18 - 52 Week Range
2.10 - 23.01 - Volume
176,870 - Avg. Volume
1,388,603 - Market Cap (intraday)
18.1M - Beta (5Y Monthly) 0.97
- PE Ratio (TTM)
-- - EPS (TTM)
-68.17 - Earnings Date May 1, 2025 - May 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
www.portagebiotech.comRecent News: PRTG
View More
Performance Overview: PRTG
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRTG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRTG
View MoreValuation Measures
Market Cap
19.47M
Enterprise Value
17.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
13.92
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.45%
Return on Equity (ttm)
-198.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-67.28M
Diluted EPS (ttm)
-68.17
Balance Sheet and Cash Flow
Total Cash (mrq)
1.76M
Total Debt/Equity (mrq)
4.03%
Levered Free Cash Flow (ttm)
-6.31M